The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Helix BioMedix Strengthens Intellectual Property Position

12-Jan-2012 | Source : | Visits : 8391
BOTHELL, WASHINGTON - Helix BioMedix Inc., a developer of bioactive peptides, announced in a press release that it has been granted four new US and foreign patents, further strengthening the company’s intellectual property assets.

The patents focus on dermatological health, where the company continues to build its industry leading intellectual property portfolio. The patents include:

- US patent number 8,071,555 B2, entitled “Protective Skin Care Peptides”;
- European patent number 2027152, entitled “Peptide Fragments for Inducing Synthesis of Extra Cellular Matrix Proteins”;
- Australian patent number 2006212922, entitled “Antimicrobial Hexapeptides”; and
- Mexican patent number 288451, entitled “Short Bio-Active Peptides for Cellular and Immunological Modulation”.

Dr. Lijuan Zhang, Senior Director of R&D Innovation, commented: “Helix BioMedix continues to develop new and innovative technology focused on our core capabilities in dermatology, anti-infectives, cosmeceuticals and personal care. Our ongoing research into the vital functions of the human innate immunity system has led to the identification of a wide array of distinct peptide sequences. Innate immunity peptides act as a first line of defense in the skin and play a key role in the processes controlling infection, modulating inflammation, healing wounds and building tissue.”

R. Stephen Beatty, President and CEO stated: “We are pleased to continue our mission of creating value for our shareholders. These patents offer added opportunities for the development of our own products and for use with our peptide distribution partners. We expect to receive additional patent issuances during 2012.”

Related Articles